Nadis® technology enhances ABL’s footprint in monitoring infectious and chronic diseases in France and soon worldwide
LUXEMBOURG, June 3, 2016 /PRNewswire-iReach/ -- Advanced Biological Laboratories (ABL) today announced that it has signed a definitive agreement to acquire Fedialis Medica, a company headquartered in France. Fedialis Medica is a provider of healthcare services and proprietary information technology dedicated to improving patient disease management. Fedialis Medica partner with clinicians, hospitals, consultation rooms, researchers and others across the healthcare system to deliver optimized care, primarily to patients infected with HIV / AIDS and viral hepatitis. The main product is Nadis® HIV. It is used in France at more than 130 infectious diseases sites for clinical and research practice. These include all the major medical university hospitals.
This acquisition also affords ABL complete ownership of the Nadis® platform technology and immediate commercial presence in France. Nadis meets all the requirements for routine medical care and research, with the prescriptions system and required data certified by the Haute Autorité de Santé (National Health Authority in France). It complies with health data protection rules and information security policies. The aforementioned and existing laboratory and hospital information systems interfaces allow this data to feed the French national statistics database for HIV (Inserm, DOMEVIH).
“This technology has the potential to provide French healthcare professionals instant access to accurate demographics, medical history and latest laboratory results, in real-time. This can lead to quick and informed treatment decisions,” said Ronan Boulmé, Vice-President for R&D and Operations of ABL. “Fast, user- friendly, scalable and robust informatics solutions make a big difference to the quality of care and impact of the work of clinicians and researchers.”
“We are very excited to continue the tremendous work done by Fedialis Medica and their long-standing clinical partners in France, healthcare professionals and experts using the Nadis® system daily,” said Dr Chalom Sayada, Administrateur Délégué of ABL.
“We commit to continue serving all the French infectious diseases units with Nadis®, together with ABL’s experienced integrated IT and health value chain. Our customers will benefit from insightful and worthwhile clinical, biological and genomic information. We will also remain committed to supporting multiple clinical software applications serving different markets worldwide. ABL Group is the ideal company to deliver on the promise of Nadis® technology, products and pipeline and provide high quality technical support to all the current and future healthcare users. Simultaneously we will continue to grow our multi skilled team of bioinformatics scientists, computer scientists and software engineers,” added Dr Sayada.
Financial details of the agreement were not disclosed.
About ABL
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC® and the DPM which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL’s products also received CE-marking for IVD use. ABL’s products, ViroScore® Suite and DeepChek®, are for research use only in the United States, and the upcoming data processing module is a FDA registered class I medical device. ABL’s products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems that combe standard and high-throughput Next Generation Sequencing data. ABL’s DeepChek® SingleRound HIV and Hepatitis C Virus (HCV) Genotyping and Sequencing assays are the first two in its virology reagents portfolio. These are currently available for Research Use Only.
Media Contact: Chalom Sayada, Advanced Biological Laboratories (ABL) SA, +325 2638 9676, contact@ablsa.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Advanced Biological Laboratories
